Short answer
PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on June 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events). Convertible Notes sold privately under Securities Act Section 4(a)(2) and Rule 144A to qualified institutional buyers.
PTC THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Convertible Notes sold privately under Securities Act Section 4(a)(2) and Rule 144A to qualified institutional buyers
- No resale registration planned for the Notes or conversion shares, limiting liquidity and potentially broad investor access
- Conversion could create future common-stock dilution for existing shareholders
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 signals a newly created direct financial obligation or off-balance-sheet arrangement
Item 8.01 · Other Events
- $328.8M net offering proceeds allocated partly to debt reduction
- $222.0M principal of Existing Convertible Notes repurchased for cash
- Existing Convertible Notes outstanding reduced to $55.5M
- Privately negotiated repurchases with certain noteholders, concurrent with new-note pricing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PTC THERAPEUTICS, INC. 8-K filings
Get the next PTCT 8-K as it lands
Follow PTCT for push alerts, or ask the research agent what this filing means.